DOI:
10.1055/s-00000145
Dialyse aktuell
LinksClose Window
References
Mosenzon O, Wiviott SD, Cahn A. et al
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial.
Lancet Diabetes Endocrinol 2019;
7: 606-617 doi:10.1016/S2213-8587(19)30180-9
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.